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OBJECTIVEdTo examine the association of hemoglobin (Hb) A1c variability with microvas-
cular complications in the large cohort of subjects with type 2 diabetes from the Renal Insuffi-
ciency And Cardiovascular Events (RIACE) Italian Multicenter Study.
RESEARCHDESIGNANDMETHODSdSerial (3–5) HbA1c values collected in a 2-year
period before enrollment were available from 8,260 subjects from 9 centers (of 15,773 patients
from 19 centers). HbA1c variability was measured as the intraindividual SD of 4.52 6 0.76
values. Diabetic retinopathy (DR) was assessed by dilated funduscopy. Chronic kidney disease
(CKD) was defined based on albuminuria, as measured by immunonephelometry or immuno-
turbidimetry, and estimated glomerular filtration rate (eGFR) was calculated from serum creat-
inine.
RESULTSdMedian and interquartile range of average HbA1c (HbA1c-MEAN) andHbA1c-SDwere
7.57% (6.86–8.38) and 0.46% (0.29–0.74), respectively. The highest prevalence of microalbuminu-
ria, macroalbuminuria, reduced eGFR, albuminuric CKD phenotypes, and advanced DR was ob-
servedwhenbothHbA1c parameterswere above themedian and the lowestwhenbothwere below the
median. Logistic regression analyses showed that HbA1c-SD adds toHbA1c-MEAN as an independent
correlate of microalbuminuria and stages 1–2 CKD and is an independent predictor of macroalbu-
minuria, reduced eGFR, and stages 3–5 albuminuric CKD, whereas HbA1c-MEAN is not. The oppo-
site was found for DR, whereas neither HbA1c-MEAN nor HbA1c-SD affected nonalbuminuric CKD.
CONCLUSIONSdIn patients with type 2 diabetes, HbA1c variability affects (albuminuric)
CKD more than average HbA1c, whereas only the latter parameter affects DR, thus suggesting a
variable effect of these measures on microvascular complications.
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Compelling evidence shows thatlong-term glycemic control, as ex-pressed by hemoglobin (Hb) A1c
levels, is the main risk factor for the de-
velopment of microvascular complica-
tions in type 1 (1) and type 2 diabetes
(2), with risk rising exponentially as
HbA1c increases. Another risk factor re-
lated to hyperglycemia is variability of
glycemic control that comprises “glucose
variability” and “HbA1c variability.” Glu-
cose variability relates to within-day fluc-
tuations of glycemia, especially as a
consequence of meals (3), and may even-
tually reflect in increased HbA1c levels.
Conversely, HbA1c variability relates to
changes in glycemia over longer periods
of time that result in change in HbA1c
from one visit to the next (4).
Retrospective analyses of data from
the Diabetes Control and Complications
Trial (DCCT) have not confirmed that
within-day glucose variability predicts the
development of microvascular complica-
tions (5–7), although this was not a pre-
specified end point of the study.
However, a prospective study specifically
addressing this issue did not show any
effect of within-day glucose fluctuations
on cardiovascular events (8). Conversely,
retrospective analyses of the DCCT (9)
and the Finnish Diabetic Nephropathy
(FinnDiane) Study (10) have suggested
that HbA1c variability is an independent
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risk factor for the development of diabetic
retinopathy (DR) and nephropathy (DN)
in individuals with type 1 diabetes. More-
over, HbA1c variability was shown to be
an independent variable that added to the
effect of HbA1c on the risk of microalbu-
minuria in adolescent patients with type 1
diabetes from the Oxford Regional Pro-
spective Study and the Nephropathy
Family Study (11). Very recently, two
prospective cohort studies from Japan
and Taiwan, the Tsukuba Kawai Diabetes
Registry 2 (12) and the Diabetes Manage-
ment through an Integrated Delivery Sys-
tem project (13), have shown that HbA1c
variability is associated with microalbu-
minuria, even after adjustment for known
predictors of albuminuria, in 812 and 821
patients with type 2 diabetes, over a 4.3-
year and a 6.2-year follow-up, respec-
tively.
To further address this issue, we used
the large cohort of Caucasian subjects
with type 2 diabetes from the Renal In-
sufficiency And Cardiovascular Events
(RIACE) Italian Multicenter Study to as-
sess whether the baseline status of DN and
DR was independently associated with
HbA1c variability as assessed retrospec-
tively from HbA1c values obtained during
the 2-year period preceding the enroll-
ment. This study assessed DN by albu-
minuria and the estimated glomerular
filtration rate (eGFR), and patients were
stratified by chronic kidney disease
(CKD) stage or phenotype.
RESEARCH DESIGN AND
METHODS
Study cohort
We used the data collected at the baseline
visit for the RIACE Italian Multicenter
Study (registered with ClinicalTrials.gov,
NCT00715481; URL http://clinicaltrials.
gov/ct2/show/NCT00715481), an obser-
vational, prospective cohort study on the
effect of eGFR onmorbidity and mortality
from cardiovascular disease (CVD) in
type 2 diabetes.
The RIACE cohort consisted of
15,933 Caucasian patients with type 2
diabetes (defined by the American Di-
abetes Association criteria) consecutively
attending 19 hospital-based diabetes clin-
ics of the National Health Service
throughout Italy (see Supplementary
Data) in years 2007–2008. Exclusion cri-
teria were dialysis or renal transplanta-
tion. The study protocol was reviewed
by the locally appointed ethics boards.
The quality and completeness of data
were controlled, and 160 patients were
excluded due to missing or implausible
values. The remaining 15,773 subjects
were subsequently analyzed. Multiple
HbA1c values (3–5, mean 6 SD: 4.52 6
0.76) serially measured during the 2-
year period preceding the enrollment
were available from nine centers for
8,290 patients (52.6% of the entire co-
hort). CVD risk factors and complications
were determined as part of the baseline
assessment. Measurements were under-
taken from a standardized protocol across
study centers.
CVD risk factors
All patients underwent a structured in-
terview to collect information on age,
smoking status, known diabetes dura-
tion, and current glucose-, blood pressure
(BP)-, and lipid-lowering treatments as
well as antiplatelet and anticoagulant
therapy, with indication of the class of
drug. Weight and height were assessed,
with calculation of BMI. BP was measured
with a sphygmomanometer after a 5-min
rest. Triglycerides and total and HDL
cholesterol were determined by standard
analytical methods; LDL cholesterol was
calculated by the Friedewald formula.
Hypertension was defined as systolic BP
$140 mmHg and/or diastolic BP $90
mmHg and/or antihypertensive treat-
ment. Dyslipidemia was defined as high
($100 mg/dL) LDL cholesterol and/or
lipid-lowering treatment.
Complications
The presence of CKD at baseline was
assessed by albuminuria and serum cre-
atinine. As previously reported in detail
(14), the albumin excretion rate (AER)
was obtained from timed (24 h) urine
collections or calculated from the albumin-
to-creatinine ratio in early-morning, first-
voided urine samples, in the absence
of symptoms and signs of urinary tract
infection or other interfering clinical con-
ditions. Albuminuria was measured in
one to three fresh urine samples for each
patient by immunonephelometry or im-
munoturbidimetry, and the geometric
mean was used for analysis in case of mul-
tiple measurements. In subjects with mul-
tiple measurements (4,062 with at least
two and 2,310 with three values), the
concordance rate between the first value
and the geometric mean was.90% for all
classes of albuminuria (14). As an external
quality control of urinary albumin assays,
50 samples from each center were reana-
lyzed at the reference laboratory using the
immunonephelometry method to verify
that the coefficients of variation between
the peripheral and the central values
were ,15% at least in the relevant clini-
cal range of 15–500 mg/L, which was the
case for 94% of samples (14). Patients
were then assigned to one of the follow-
ing categories of albuminuria (mg/24 h):
normoalbuminuria (AER ,30), microal-
buminuria (AER 30–299), or macroal-
buminuria (AER $300).
Serum (and urine) creatinine was
measured by the modified Jaffe method.
One to three measurements were ob-
tained for each patient, and eGFR was
calculated by the four-variable Modifica-
tion of Diet in Renal Disease study equa-
tion (15), using the mean serum
creatinine value in case of multiple mea-
sures, as reported in previous publications
(14,16,17). Patients were then assigned to
one of the following categories of eGFR
(mL/min/1.73 m2): 1 ($90), 2 (60–89),
3 (30–59), 4 (15–29), and 5 (,15). Fi-
nally, subjects were classified as having
no CKD or CKD stages 1–5, based on
the presence or absence of micro- or mac-
roalbuminuria, and the value of the eGFR,
as calculated by the Modification of Diet
in Renal Disease study equation, accord-
ing to the National Kidney Foundation’s
Kidney Disease Outcomes Quality Initia-
tive (18). Patients assigned to CKD stages
(and GFR classes) 4 and 5 were pooled. As
previously reported (17), CKD patients
were further classified as having one of
the following CKD phenotypes: albumin-
uria alone (stages 1–2 CKD), reduced
eGFR alone (stage$3 CKD without albu-
minuria), or both (stage $3 CKD with
albuminuria).
The presence of DR at baseline was
assessed by dilated funduscopy. In each
center, an expert ophthalmologist was
asked to complete a standardized report
form and to classify DR as absent, mild,
moderate, or severe nonproliferative DR
(NPDR), proliferative DR (PDR), and
maculopathy, according to the Global
Diabetic Retinopathy Project Group
(19). Patients were classified based on
the actual fundus appearance or the reti-
nal disease condition that had eventually
required a previous photocoagulation or
surgical treatment. On the basis of the
worst eye, patients with NPDR of mild
(microaneurysms only) or moderate (mi-
croaneurysms and other microvascular
lesions) degree were classified as having
nonadvanced DR, whereas those with se-
vere NPDR or pre-PDR (i.e., microaneur-
ysms/hemorrhages in four quadrants, or
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venous beadings in two quadrants, or in-
traretinal microvascular abnormalities in
one quadrant), PDR (i.e., neovasculariza-
tion from the disc or from elsewhere, vit-
reous hemorrhages, or tractional retinal
detachment), maculopathy (retinal thick-
ening or hard exudates distant from, ap-
proaching, or involving the center of the
macula), or blindness (if less than 1/10
normal vision or 20/200 on the Snellen
test) were grouped into the advanced
DR category (20).
Prevalent CVD at baseline was as-
sessed from medical history by recording
previously documented major acute CVD
events, including myocardial infarction,
stroke, foot ulcer or gangrene, amputa-
tion, coronary, carotid, and lower limb
revascularization, and surgery for aortic
aneurysm. CVD events were adjudicated
based on hospital discharge records or
specialist visits by an ad hoc committee in
each center (21).
HbA1c variability
HbA1c was measured in each center by
high-performance liquid chromatogra-
phy using DCCT-aligned methods. Aver-
age HbA1c and HbA1c variability was
calculated for each patient as the intrain-
dividual mean (HbA1c-MEAN) and SD
(HbA1c-SD), respectively, for HbA1c val-
ues obtained during the 2-year period
preceding recruitment, including that ob-
tained at the enrollment. The interindi-
vidual difference in the number of
HbA1c assessments (a few values would
make the SD apparently greater than
many values) was adjusted according to
the formula: adj-HbA1c-SD = SD/![n/(n-
1)] (9,11). Furthermore, as a normalized
measure of variability, the coefficient of
variation of HbA1c (HbA1c-CV) was cal-
culated as the ratio of HbA1c-SD and
HbA1c-MEAN to correct for larger SDs
due to higher absolute values of HbA1c-
MEAN (10).
Statistical analysis
Data are expressed as median (interquar-
tile range [IQR]) and/or mean 6 SD for
continuous variables and number of sub-
jects and percentage for categorical varia-
bles. Patients were stratified by presence
and severity of microvascular complica-
tions. Continuous variables were com-
pared by the Student t test or one-way
ANOVA for normally distributed varia-
bles and by Mann-Whitney U test or
Kruskal-Wallis test for variables with a
skewed distribution. Pearson x2 was ap-
plied to categorical variables.
Logistic regression analyses with
backward variable selection (probability
for removal .0.10) were performed to
assess whether increments in HbA1c-
MEAN (model 1), increments of HbA1c-
MEAN and HbA1c-SD (model 2), and
quartiles of both variables (model 3)
were independent correlates of microvas-
cular complications compared with no
complications. Covariates were, age,
BMI, sex, known disease duration, smok-
ing habits, triglycerides, HDL cholesterol,
hypertension, dyslipidemia, previous ma-
jor CVD events, specific treatments, and
eGFR and albuminuria categories if DR
was the dependent variable or DR catego-
ries if renal parameters were the depen-
dent variable. Results of these analyses
were expressed as odd ratios (ORs) with
their 95% CIs. Logistic regression analy-
ses were repeated entering adj-HbA1c-SD
(or HbA1c-CV) instead of HbA1c-SD as a
measure of HbA1c variability.
All P values were two-sided, and a
P value,0.05 was considered statistically
significant. Statistical analyses were per-
formed using SPSS 13.0 software (SPSS
Inc., Chicago, IL).
RESULTS
Patients’ characteristics
Participants included in this analysis (i.e.,
those with 3 to 5 HbA1c values) had a me-
dian (IQR) age and duration of diabetes at
enrollment of 68 (61–74) and 14 (7–23)
years, respectively. The male-to-female
ratio was 57:43. Likely due to longer dis-
ease duration, these subjects showed a
worse CVD risk profile and a higher prev-
alence of any CVD event and were more
frequently receiving treatment with glu-
cose-, lipid-, and BP-lowering drugs than
those excluded from the analysis due to
unavailability of serial HbA1c measure-
ments (Supplementary Table 1). HbA1c-
MEAN of participants was 7.57% (6.86–
8.38), HbA1c-SD was 0.46 (0.29–0.74),
and adj-HbA1c-SD was 0.40 (0.25–
0.65). The variability measures of
HbA1c-SD and adj-HbA1c-SD were
closely related to HbA1c-MEAN (r =
0.428 and r = 434, respectively, P ,
0.01 for both). Consistently, HbA1c-SD
(and adj-HbA1c-SD) progressively in-
creased throughout HbA1c-MEAN quar-
tiles and vice versa (Supplementary Table
2); likewise, HbA1c-CV progressively
increased with HbA1c-MEAN quartiles
(Supplementary Table 2) and also with
HbA1c-SD quartiles (Supplementary
Table 3).
Average HbA1c and HbA1c variability
Increasing HbA1c-MEAN was associated
with longer diabetes duration and a
more adverse CVD risk profile, and sub-
jects were more frequently taking insulin
alone or combined with an oral hypoglyce-
mic agent, taking lipid-lowering drugs, and
receiving antihypertensive treatment (in-
cluding inhibitors of the renin-angiotensin
system). Prevalence of albuminuria (micro-
and macroalbuminuria) and DR (nonad-
vanced and advanced) increased markedly
across HbA1c-MEAN quartiles. Rates of
reduced eGFR (,60 mL/min/1.73m2),
stages 1–2 CKD, and stages 3–5 albumin-
uric CKD increased by 49, 68, and 88%,
respectively, from the lowest to the highest
HbA1c-MEAN quartile, whereas the rate
of stages 3–5 nonalbuminuric CKD did
not change significantly (Supplementary
Table 2).
Higher HbA1c variability (i.e., higher
HbA1c-SD) was associated with younger
age, lower age at diabetes diagnosis,
shorter diabetes duration, higher HbA1c
and BMI values, and a more adverse lipid
profile, with no differences in BP levels.
Prevalence of micro- and macroalbumi-
nuria, reduced eGFR, stages 1–2 CKD,
stages 3–5 albuminuric CKD, and ad-
vanced DR increased progressively with
increasing HbA1c-SD, whereas that of
stages 3–5 nonalbuminuric CKD and
nonadvanced DR did not change (Supple-
mentary Table 3). Findings were similar
for HbA1c-CV, suggesting that differences
among HbA1c-SD quartiles were not
solely attributable to differences in abso-
lute HbA1c-MEAN values (data not
shown).
In Table 1, prevalence rates are given
for HbA1c-MEAN and HbA1c-SD above
and below the population median values.
For micro- and macroalbuminuria, re-
duced eGFR, stages 1–2 CKD, stages
3–5 albuminuric CKD, and advanced
DR, the highest prevalence rates were ob-
served when HbA1c-MEAN and HbA1c-
SD were above the median; these subjects
also showed the worst CVD risk profile.
Conversely, the lowest prevalence for the
above microvascular end points was
found when both measures were below
the median. No differences among the
four groups were observed for stages 3–
5 nonalbuminuric CKD. Interestingly,
patients above the median for HbA1c-
MEAN and below the median for
HbA1c-SD had similar prevalence rates
of albuminuria, reduced eGFR, and
CKD phenotypes as patients below the
median for HbA1c-MEAN and above the
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Table 1dMain clinical characteristics and prevalence of retinopathy and renal disease in subjects stratified according to HbA1c-MEAN
and HbA1c-SD above and below the cohort median values
Groups
HbA1c-MEAN below HbA1c-MEAN above
Variables HbA1c-SD below HbA1c-SD above HbA1c-SD below HbA1c-SD above P*
n (%) 2,779 (33.5) 1,367 (16.5) 1,366 (16.5) 2,778 (33.5)
HbA1c-MEAN (%) 6.70 6 0.58 6.91 6 0.51 8.34 6 0.73 8.77 6 0.98
HbA1c-SD (%) 0.27 6 0.10 0.76 6 0.32 0.32 6 0.09 0.98 6 0.56
HbA1c-CV 4.08 6 1.45 10.97 6 4.60 3.81 6 1.12 11.14 6 6.10
Adj-HbA1c-SD (%) 0.24 6 0.09 0.66 6 0.27 0.28 6 0.08 0.86 6 0.48
Males, n (%) 1,627 (58.5) 836 (61.2) 677 (49.6) 1,586 (57.1) ,0.0001
Age (years) 67.4 6 9.7 66.2 6 10.1 69.1 6 9.3 66.6 6 10.2 ,0.0001
At diabetes diagnosis 53.5 6 10.5 54.2 6 10.8 49.6 6 10.4 50.0 6 10.4 ,0.0001
Diabetes duration (years) 14.0 6 10.2 12.0 6 9.6 19.4 6 9.6 16.6 6 10.0 ,0.0001
Smoking, n (%) ,0.0001
Never 1,480 (53.2) 784 (57.4) 691 (50.5) 1,529 (55.0)
Former 911 (32.8) 407 (29.8) 451 (33.0) 787 (28.3)
Current 388 (14.0) 175 (12.8) 225 (16.5) 462 (16.6)
BMI (kg/m2) 28.3 6 4.7 29.0 6 5.1 28.5 6 5.1 29.5 6 5.2 ,0.0001
Triglycerides (mmol/L) 0.41 6 0.80 1.54 6 0.87 1.52 6 0.93 1.68 6 1.00 ,0.0001
Cholesterol (mmol/L)
Total 4.74 6 0.90 4.73 6 0.93 4.77 6 0.91 4.76 6 0.94 ns
HDL
Males 1.28 6 0.34 1.21 6 0.32 1.24 6 0.30 1.19 6 0.31 ,0.0001
Females 1.43 6 0.37 1.39 6 0.36 1.40 6 0.36 1.35 6 0.36 ,0.0001
LDL 2.77 6 0.77 2.75 6 0.82 2.76 6 0.78 2.76 6 0.85 ns
Non-HDL 3.40 6 0.85 3.44 6 0.90 3.45 6 0.88 3.51 6 0.96 ,0.0001
Dyslipidemia, n (%) 2,323 (83.6) 1,117 (81.7) 1,167 (85.4) 2,296 (82.6) ns
BP (mmHg)
Systolic 138.6 6 17.9 138.4 6 18.0 141.6 6 17.8 140.2 6 19.0 ,0.0001
Diastolic 78.2 6 8.9 78.8 6 9.2 78.6 6 8.9 78.6 6 9.6 ns
Hypertension, n (%) 2,350 (84.6) 1,146 (83.8) 1,229 (90.0) 2,383 (85.8) ,0.0001
Diabetes treatment, n (%) ,0.0001
Diet 674 (23.3) 132 (9.7) 41 (3.0) 60 (2.2)
OHA 1,801 (64.8) 1,022 (74.8) 869 (63.6) 1,636 (58.9)
OHA + insulin 91 (3.3) 58 (4.2) 184 (13.5) 442 (15.9)
Insulin 240 (8.6) 155 (11.3) 272 (19.9) 640 (23.0)
Lipid-lowering treatment, n (%) 1,376 (49.5) 611 (44.7) 721 (52.8) 1,408 (50.7) ,0.0001
Antihypertensive treatment, n (%) 2,029 (73.0) 971 (71.0) 1,039 (76.1) 2,043 (73.5) 0.028
ACE-I/ARB treatment, n (%) 1,614 (58.1) 789 (57.7) 873 (63.9) 1,715 (61.7) ,0.0001
Albuminuria, n (%) ,0.0001
Normoalbuminuria 2,182 (78.5) 1,029 (75.3) 998 (73.1) 1,845 (66.4)
Microalbuminuria 498 (17.9) 284 (20.8) 305 (22.3) 742 (26.7) ,0.0001
Macroalbuminuria 100 (3.6) 54 (4.0) 63 (4.6) 191 (6.9) ,0.0001
Serum creatinine (mmol/L) 84.0 6 34.5 86.6 6 39.8 84.0 6 35.4 85.7 6 31.8 ns
eGFR, n (%) ,0.0001
$90 mL/min/1.73 m2 730 (26.3) 423 (30.9) 338 (24.7) 757 (27.2)
60–89 mL/min/1.73 m2 1,596 (57.4) 675 (49.4) 733 (53.7) 1,396 (50.3) ,0.0001
30–59 mL/min/1.73 m2 417 (15.0) 243 (17.8) 272 (19.9) 569 (20.5) ,0.0001
,30 mL/min/1.73 m2 36 (1.3) 26 (1.9) 23 (1.7) 56 (2.0) 0.194
CKD phenotype, n (%) ,0.0001
No CKD 1,907 (68.6) 867 (63.4) 819 (60.0) 1,526 (54.9)
Stages 1–2 CKD 419 (15.1) 231 (16.9) 252 (18.4) 627 (22.6) ,0.0001
Stage $3 CKD
Without albuminuria 274 (9.9) 162 (11.9) 179 (13.1) 319 (11.5) 0.013
With albuminuria 179 (6.4) 107 (7.8) 116 (8.5) 306 (11.0) ,0.0001
Retinopathy, n (%) ,0.0001
Continued on p. 2305
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median for HbA1c-SD, suggesting distinct
but comparable effects of average HbA1c
and HbA1c variability. This finding was
not observed for nonadvanced and ad-
vanced DR. Indeed, DR was more fre-
quent in subjects with HbA1c-MEAN
above the median irrespective of HbA1c-
SD levels.
Multiple logistic regression models
Because of several potential confounding
factors for the association between HbA1c
variability and prevalence of microvascu-
lar complications, we used logistic regres-
sion as a multivariate analysis. Even after
adjusting for several CVD risk factors and
also for DR, HbA1c-SD was a significant
correlate of microalbuminuria, even inde-
pendently of HbA1c-MEAN. Moreover,
HbA1c-SD was also an independent pre-
dictor of macroalbuminuria and reduced
eGFR, whereas HbA1c-MEAN was not
(Table 2). Interestingly, whereas HbA1c-
MEAN and HbA1c-SD were both inde-
pendent correlates of stages 1–2 CKD
and only HbA1c-SD was an independent
predictor of stages 3–5 albuminuric CKD,
neither HbA1c-MEAN nor HbA1c-SD was
independently associated with stages 3–5
nonalbuminuric CKD (Table 3). On the
contrary, although HbA1c-MEAN was as-
sociated with both nonadvanced and ad-
vanced DR independently of several
variables, including albuminuria (nonad-
vanced DR) or both albuminuria and
eGFR (advanced DR), HbA1c-SD was not
an independent correlate of DR (Table 4).
Where both HbA1c-MEAN andHbA1c-SD
entered as independent correlates in
model 3 logistic regression, the ORs of
these two variables were quite similar,
reaching statistically significant effects in
the highest quartile. In all models, ex-
pressing HbA1c variability as adj-HbA1c-
SD or HbA1c-CV instead of HbA1c-SD did
not change the association with risk of
microvascular complications.
CONCLUSIONSdRecent evidence
suggests that microvascular complica-
tions are predicted not only by HbA1c lev-
els but also by HbA1c variability from one
visit to the next, independently of average
HbA1c and known risk factors for micro-
angiopathy, both in type 1 (9–11) and
type 2 (12,13) diabetes. At variance with
these previous reports (9–13), our study
covers the entire spectrum of renal disease
in diabetic individuals, with the sole ex-
ception of end-stage renal disease, and
also includes DR, the other microvascular
complication, which has not been inves-
tigated in type 2 diabetes. This broader
analysis provides the first evidence of a
wide spectrum of associations of average
HbA1c and HbA1c variability with micro-
vascular complications in subjects with
type 2 diabetes, thus suggesting that dif-
ferent mechanisms might link glycemic
control to microvascular abnormalities
in these individuals. In fact, both mea-
sures correlated only with microalbumi-
nuria (and stages 1–2 CKD) to the same
extent and independently of each other
and of known risk factors. In contrast,
HbA1c-SD was associated with macroal-
buminuria and albuminuric stages 3–5
CKD, independently of HbA1c-MEAN,
even after adjustment for other known
predictors of DN, whereas HbA1c-MEAN
was not. Conversely, HbA1c-SD did not
add to HbA1c-MEAN as an independent
correlate of both nonadvanced and ad-
vanced DR. Finally, neither HbA1c-
MEAN nor HbA1c-SD was independently
associated with reduced eGFR and non-
albuminuric stages 3–5 CKD.
Concerning microalbuminuria, our
data support two recent analyses of indi-
viduals with type 2 diabetes from Japan
(12) and Taiwan (13), where HbA1c vari-
ability predicted the development of mi-
croalbuminuria independently of average
HbA1c in a mean follow-up period of 4.3
and 6.2 years, respectively. Our results
are also in accordance with previous re-
ports in subjects with type 1 diabetes (9–
11). In particular, Kaplan-Meier survival
curves in the FinnDiane Study (10) dem-
onstrated that patients above the median
for HbA1c-MEAN and below the median
for HbA1c-SD had similar rate of any pro-
gression in renal status (as defined as a
shift to a higher albuminuria level or to
end-stage renal disease) as patients below
the median for HbA1c-MEAN and above
the median for HbA1c-SD. This is consis-
tent with our finding that groups discor-
dant for below and above median values
of HbA1c-MEAN and HbA1c-SD showed
similar rates of microalbuminuria (and
stages 1–2 CKD), suggesting a distinct
but equally important effect of both aver-
age HbA1c and HbA1c variability.
Concerning other DN markers and
CKD phenotypes, although rates of mac-
roalbuminuria, reduced eGFR, and stages
3–5 albuminuric CKD were also similar
between subjects above the median for
HbA1c-MEAN and below the median for
HbA1c-SD and those vice versa, logistic
regression analysis showed that only
HbA1c-SD was independently associated
with macroalbuminuria and stages 3–5
albuminuric CKD, whereas neither
HbA1c-MEAN nor HbA1c-SD correlated
with reduced eGFR or stages 3–5 nonal-
buminuric CKD, although the highest
HbA1c-SD quartiles did. Altogether, these
results suggest that HbA1c variability
might be even more important than aver-
age HbA1c in conferring overall DN risk;
however, longitudinal studies are needed
to clarify this issue. Moreover, these data
confirm (and extend to HbA1c variability)
our previous observation that reduced
eGFR and, particularly, the nonalbumi-
nuric CKD phenotype, in which an
eGFR ,60 mL/min/1.73 m2 develops in
the absence of albuminuria, are not related
to glycemic control (17). This further sup-
ports the concept that macroangiopathy,
Table 1dContinued
Groups
HbA1c-MEAN below HbA1c-MEAN above
Variables HbA1c-SD below HbA1c-SD above HbA1c-SD below HbA1c-SD above P*
None 2,344 (84.3) 1,139 (83.3) 889 (65.1) 1,897 (68.3)
Nonadvanced 300 (10.8) 142 (10.4) 322 (23.6) 506 (18.2) ,0.0001
Advanced 135 (4.9) 86 (6.3) 155 (11.3) 375 (13.5) ,0.0001
Values are mean6 SD for continuous variables and n (%) for categorical variables. ARB, angiotensin-receptor blocker; OHA, oral hypoglycemic agent. *P values for
comparison between quartiles using the one-way ANOVA for parametric or the corresponding Kruskal-Wallis test for nonparametric (triglycerides) continuous
variables and the x2 test for categorical variables.
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rather than microangiopathy, is the pre-
vailing renal pathology underlying nonal-
buminuric CKD (17), which nowadays is
the predominant form of renal impair-
ment in subjects with type 2 diabetes
(17,22–24).
Concerning DR, our study showed
that only the rate of advanced DR in-
creased significantly with increasing
HbA1c variability and that no effect of
HbA1c-SD could be detected on nonad-
vanced or advanced DR when adjusting
for HbA1c-MEAN and other known pre-
dictors of DR. This is at variance with
findings in subjects with type 1 diabetes
showing that increasing HbA1c variability
adds to the risk of DR exceeding that pre-
dicted by average HbA1c alone (9,10).
This discrepancy has no obvious explana-
tion, especially if we consider that, again
in type 1 diabetes, a rapid improvement of
glycemic control can lead to a short-term
worsening of DR, followed by a net im-
provement in the long-term (25), which
could be lost if another HbA1c increment
ensues. It might be speculated that HbA1c
variability is of lower magnitude in sub-
jects with type 2 diabetes and, hence, its
effect is masked by that of average HbA1c
and possibly of other variables related to
Table 2dLogistic regression analysis with backward variable selection of independent correlates of micro- and macroalbuminuria, and
eGFR <60 mL/min/1.73 m2 versus normoalbuminuria and, respectively, eGFR ‡60 mL/min/1.73 m2
Microalbuminuria Macroalbuminuria eGFR ,60 mL/min/1.73 m2
Variables OR (95% CI) P OR (95% CI) P OR (95% CI) P
Age, 3 year 1.029 (1.022–1.035) 0.0001 1.031 (1.017–1.044) 0.0001 1.101 (1.092–1.109) 0.0001
Diabetes duration, 3 year 1.013 (1.001–1.026) 0.032
Gender, male 2.189 (1.938–2.473) 0.0001 2.746 (2.137–3.530) 0.0001 0.447 (0.391–0.511) 0.0001
BMI 3 unit 1.028 (1.016–1.040) 0.0001 1.049 (1.026–1.072) 0.0001 1.028 (1.015–1.042) 0.0001
Smoking 0.0001 0.0001
Never 1.0 1.0
Former 1.026 (0.904–1.165) 0.690 1.185 (0.922–1.523) 0.185
Current 1.387 (1.182–1.626) 0.0001 2.043 (1.519–2.749) 0.0001
Triglycerides, 3 0.0113 mmol/L 1.002 (1.002–1.003) 0.0001 1.005 (1.004–1.006) 0.0001 1.003 (1.002–1.004) 0.0001
HDL cholesterol, 3 0.259 mmol/L 0.984 (0.979–0.989) 0.0001
Hypertension 1.981 (1.632–2.405 0.0001 5.329 (2.801–10.140) 0.0001 1.551 (1.219–1.974) 0.0001
Previous CVD event 1.213 (1.073–1.372) 0.002 1.381 (1.102–1.732) 0.005 1.772 (1.552–2.024) 0.0001
Diabetes treatment 0.020 0.0001 0.0001
Diet 1.0 1.0 1.0
OHA 1.151 (0.939–1.411) 0.177 1.247 (0.770–2.021) 0.369 0.830 (0.667–1.034) 0.096
OHA + insulin 1.198 (0.913–1.573) 0.192 1.792 (1.018–3.156) 0.043 0.852 (0.637–1.139) 0.280
Insulin 1.422 (1.114–1.816) 0.005 2.892 (1.719–4.864) 0.0001 1.913 (1.492–2.453) 0.0001
Albuminuria 0.0001
Normoalbuminuria 1.0
Microalbuminuria 1.619 (1.404–1.868) 0.0001
Macroalbuminuria 5.306 (4.154–6.778) 0.0001
Retinopathy 0.0001 0.0001 0.0001
None 1.0 1.0 1.0
Nonadvanced 1.396 (1.204–1.619) 0.0001 1.757 (1.324–2.331) 0.0001 1.213 (1.029–1.432) 0.022
Advanced 1.901 (1.579–2.287) 0.0001 3.782 (2.816–5.079) 0.0001 1.582 (1.294–1.934) 0.0001
Model 1
HbA1c-MEAN, 1% increment 1.159 (1.103–1.218) 0.0001 1.094 (0.996–1.202) 0.059
Model 2
HbA1c-MEAN, 1% increment 1.117 (1.058–1.179) 0.0001 0.944 (0.888–1.003) 0.062
HbA1c-SD, 1% increment 1.249 (1.105–1.410) 0.0001 1.348 (1.086–1.674) 0.007 1.151 (0.998–1.327) 0.053
Model 3
HbA1c-MEAN quartiles 0.001
Quartile 1 1.0
Quartile 2 1.018 (0.863–1.201) 0.823
Quartile 3 1.049 (0.885–1.245) 0.581
Quartile 4 1.353 (1.129–1.621) 0.001
HbA1c-SD quartiles 0.008 0.033 0.023
Quartile 1 1.0 1.0
Quartile 2 1.033 (0.878–1.217) 0.693 0.939 (0.672–1.312) 0.712 1.003 (0.838–1.201) 0.971
Quartile 3 1.142 (0.968–1.347) 0.115 1.044 (0.757–1.440) 0.792 1.233 (1.028–1.480) 0.024
Quartile 4 1.310 (1.102–1.558) 0.002 1.410 (1.031–1.929) 0.032 1.242 (1.022–1.510) 0.030
ORs of variables except HbA1c-MEAN and HbA1c-SD and their quartiles were determined by multivariate logistic analysis from model 1. The results did not change
significantly in model 2 and model 3. Other variables not in equation: dyslipidemia. OHA, oral hypoglycemic agent.
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glycemic exposure, such as diabetes du-
ration and treatments.
In addition to showing that the effect
of HbA1c variability (and of average
HbA1c) on microvascular complications
in not univocal, our study confirms the
results of previous reports indicating
that HbA1c change from one visit to the
next affects the risk of (albuminuric) DN
(9–13). In fact, although the ranges of
HbA1c-MEAN and HbA1c-SD were differ-
ent in all these studies, the effect of HbA1c
variability was at least as much as that of
average HbA1c, albeit not predominant,
except in our study showing a higher
impact of HbA1c-SD on macroalbuminu-
ria and to a lesser extent on reduced eGFR
and the combination of the two abnor-
malities in stages 3–5 albuminuric CKD.
This suggests that HbA1c variability is a
major risk factor for the development of
DN, at least of the albuminuric forms, al-
though the underlying mechanisms have
not been clarified yet (4).
One possible explanation is that even
periods of sustained hyperglycemia are “re-
membered,” thus conferring an increased
risk of microvascular complications (26),
and, hence, that the detrimental effect of
HbA1c variabilitymay bemediated through
the same mechanism underlying the “met-
abolic memory” phenomenon, including
oxidative stress (27). Indeed, in patients
with type 2 diabetes, overproduction of re-
active oxygen species was associated with
short-term glycemic excursions rather
than with sustained hyperglycemia (28),
although there are data showing a pro-
oxidant effect of longer period of hypergly-
cemia (29,30).
Another possible mechanism is that,
because the risk of microvascular compli-
cations increases exponentially as HbA1c
rises (2), subjects with higher HbA1c vari-
ability would “accumulate” a surplus of risk
Table 3dLogistic regression analysis with backward variable selection of independent correlates of stages 1–2 CKD, stages 3–5
nonalbuminuric CKD, and stages 3–5 albuminuric CKD versus no CKD
Stages 1–2 CKD Stages 3–5 nonalbuminuric CKD Stages 3–5 albumunuric CKD
Variables OR (95% CI) P OR (95% CI) P OR (95% CI) P
Age, 3 year 1.026 (1.019–1.033) 0.0001 1.113 (1.102–1.124) 0.0001 1.107 (1.093–1.121) 0.0001
Diabetes duration, 3 year 1.010 (1.000–1.020) 0.046
Gender, male 2.472 (2.152–2.841) 0.0001 0.434 (0.367–0.513) 0.0001 1.194 (0.977–1.459) 0.083
BMI, 3 unit 1.025 (1.022–1.048) 0.0001 1.038 (1.022–1.055) 0.0001 1.052 (1.032–1.072) 0.0001
Smoking 0.0001 0.007
Never 1.0 1.0
Former 0.981 (0.853–1.129) 0.792 1.233 (1.003–1.516) 0.047
Current 1.406 (1.187–1.666) 0.0001 1.514 (1.153–1.988) 0.003
Triglycerides, 3 0.0113 mmol/L 1.003 (1.002–1.003) 0.0001 1.003 (1.002–1.004) 0.0001 1.006 (1.004–1.007) 0.0001
HDL cholesterol, 3 0.259 mmol/L 0.983 (0.977–0.990) 0.0001 0.985 (0.977–0.993) 0.0001
Hypertension 2.222 (1.804–2.736) 0.0001 1.539 (1.163–2.036) 0.003 2.878 (1.905–4.347) 0.0001
Previous CVD event 1.138 (0.989–1.309) 0.071 1.802 (1.520–2.138) 0.0001 2.044 (1.694–2.466) 0.0001
Diabetes treatment 0.020 0.0001 0.0001
Diet 1.0 1.0 1.0
OHA 1.260 (1.006–1.579) 0.045 0.933 (0.715–1.217) 0.609 0.943 (0.671–1.326) 0.737
OHA + insulin 1.468 (1.092–1.975) 0.011 1.150 (0.802–1.647) 0.447 0.958 (0.613–1.497) 0.851
Insulin 1.379 (1.042–1.824) 0.025 1.881 (1.377–2.569) 0.0001 3.279 (2.266–4.746) 0.0001
Retinopathy 0.0001 0.010 0.0001
None 1.0 1.0 1.0
Nonadvanced 1.251 (1.058–1.479) 0.009 1.040 (0.835–1.296) 0.725 2.072 (1.646–2.608) 0.0001
Advanced 2.055 (1.670–2.530) 0.0001 1.539 (1.163–2.036) 0.003 3.877 (2.950–5.096) 0.0001
Model 1
HbA1c-MEAN, 1% increment 1.196 (1.132–1.264) 0.0001
Model 2
HbA1c-MEAN, 1% increment 1.156 (1.089–1.228) 0.0001
HbA1c-SD, 1% increment 1.221 (1.069–1.395) 0.003 1.331 (1.097–1.613) 0.004
Model 3
HbA1c-MEAN quartiles 0.0001
Quartile 1 1.0
Quartile 2 1.119 (0.933–1.341) 0.227
Quartile 3 1.140 (0.944–1.377) 0.175
Quartile 4 1.523 (1.244–1.864) 0.0001
HbA1c-SD quartiles 0.043 0.006
Quartile 1 1.0 1.0
Quartile 2 1.082 (0.905–1.294) 0.387 0.934 (0.711–1.228) 0.626
Quartile 3 1.139 (0.949–1.368) 0.162 1.268 (0.968–1.661) 0.084
Quartile 4 1.305 (1.080–1.578) 0.0006 1.469 (1.100–1.962) 0.009
ORs of variables except HbA1c-MEAN and HbA1c-SD and their quartiles were determined by multivariate logistic analysis from model 1. The results did not change
significantly in model 2 and model 3. Other variables not in equation: dyslipidemia. OHA, oral hypoglycemic agent.
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in the periods spent at the upper end of
their HbA1c range. This hypothesis might
be indirectly supported by our observation
that the effect of HbA1c variability is a sta-
tistically significant effect in the higher
quartile of HbA1c-SD.
Finally, the link between fluctuations
of HbA1c and risk of microvascular com-
plications might relate to the fact that pa-
tients with a higher HbA1c-SD are those
with a worse CVD risk profile and a more
intensive glucose-lowering treatment.
However, multiple regression analyses
showed that the association of HbA1c-
SD with microvascular and, particularly,
DN parameters was independent of con-
founding factors, including the higher
BMI and triglycerides and lower HDL
cholesterol levels that characterize the
metabolic syndrome, a condition associ-
ated with an increased risk of developing
renal disease (31).
Strengths of this study include the large
size of the cohort, the completeness of data,
the analysis of a contemporary dataset, the
adjustment for treatments, and, as men-
tioned above, the concurrent analysis of DR
and DN, the latter assessed as both albu-
minuria and reduced eGFR. The main
limitation is the cross-sectional design for
the assessment of DN and DR that did not
allow us to examine the effect of HbA1c var-
iability on the development ofmicrovascular
complications inuncomplicated individuals,
as in the studies of Sugawara et al. (12) and
Hsu et al. (13).
Another limitation might be that the
RIACE participants who had serial (3–5)
HbA1c measures had a longer diabetes
duration, a worse CVD risk profile, a
higher prevalence of any CVD event,
and a higher rate of treatment than those
who did not and were therefore ex-
cluded from this analysis. However, vir-
tually all subjects from the nine centers
that made available these data had more
than two HbA1c measures, indepen-
dently of their HbA1c variability,
although a selection bias cannot be ruled
out conclusively.
Other possible limitations concerning
HbA1c values are that they were per-
formed in each center as a part of the pa-
tient’s standard care, with no prespecified
Table 4dLogistic regression analysis with backward variable selection of independent correlates of nonadvanced and advanced diabetic
retinopathy versus no retinopathy
Nonadvanced retinopathy Advanced retinopathy
Variables OR (95% CI) P OR (95% CI) P
Age, 3 year 0.986 (0.979–0.994) 0.0001 0.957 (0.947–0.967) 0.0001
Diabetes duration, 3 year 1.055 (1.047–1.062) 0.0001 1.052 (1.042–1.062) 0.0001
Smoking 0.084
Never 1.0
Former 0.904 (0.748–1.093) 0.297
Current 0.753 (0.583–0.972) 0.030
Hypertension 1.317 (1.074–1.615) 0.008 2.541 (1.815–3.557) 0.0001
Previous CVD event 1.319 (1.146–1.517) 0.0001 1.288 (1.073–1.546) 0.007
Diabetes treatment 0.0001 0.0001
Diet 1.0 1.0
OHA 2.084 (1.519–2.860) 0.0001 1.887 (1.187–3.001) 0.007
OHA + insulin 4.113 (2.859–5.918) 0.0001 7.516 (4.574–12.350) 0.0001
Insulin 3.089 (2.185–4.365) 0.0001 5.529 (3.420–9.938) 0.0001
Albuminuria 0.0001 0.0001
Normoalbuminuria 1.0 1.0
Microalbuminuria 1.400 (1.206–1.625) 0.0001 1.854 (1.535–2.239) 0.0001
Macroalbuminuria 1.753 (1.324–2.320) 0.0001 3.128 (2.317–4.224) 0.0001
eGFR 0.0001
$90 mL/min/1.73 m2 1.0
60–89 mL/min/1.73 m2 1.256 (1.007–1.567) 0.43
30–59 mL/min/1.73 m2 1.734 (1.319–2.280) 0.0001
,30 mL/min/1.73 m2 3.531 (2.132–5.847) 0.0001
Model 1
HbA1c-MEAN, 1% increment 1.236 (1.167–1.308) 0.0001 1.263 (1.178–1.354) 0.0001
Model 2
HbA1c-MEAN, 1% increment 1.326 (1.245–1.412) 0.0001 1.263 (1.178–1.354) 0.0001
HbA1c-SD 1% increment 0.917 (0.758–1.110) 0.093
Model 3
HbA1c-MEAN quartiles 0.0001 0.0001
Quartile 1 1.0 1.0
Quartile 2 1.251 (1.012–1.547) 0.039 0.976 (0.976–1.308) 0.868
Quartile 3 1.684 (1.365–2.078) 0.0001 1.244 (0.942–1.643) 0.124
Quartile 4 2.314 (1.852–2.890) 0.0001 1.950 (1.495–2.544) 0.0001
HbA1c-SD quartiles
ORs of variables except HbA1c-MEAN and HbA1c-SD and their quartiles were determined by multivariate logistic analysis from model 1. The results did not change
significantly in model 2 and model 3. Other variables not in equation: gender, HDL cholesterol, triglycerides, BMI, and dyslipidemia. OHA, oral hypoglycemic agent.
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intervals between HbA1c measurements,
and that the number of measures per in-
dividual varied from 3 to 5. However,
noncentralized measurements did not af-
fect intraindividual variability, intervals
between measurements ranged from 6 to
9 months, and adj-HbA1c-SD was used to
account for difference in the number of
measures. Furthermore, although the
number of measurements was not as large
as in the study of Sugawara et al. (12) and
the period analyzed was not as long as in
the study of Hsu et al. (13), reanalyses of
these surveys showed that using 3-month
(i.e., 4–5) HbA1c measurements (12) or a
series of 2-year HbA1c values (13), as in
our study, did not change the results. Fi-
nally, potential limitations concerning
noncentralized assessment of DN and
DR have been addressed in previous
RIACE reports (14,17,20).
In conclusion, in patients with type 2
diabetes, HbA1c variability affects albu-
minuria and albuminuric CKD pheno-
types independently of (or instead of)
average HbA1c, even after adjustment for
known risk factors for microvascular
complications. On the contrary, HbA1c
variability has no effects on DR, which is
mainly dependent on HbA1c.
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